nodes	percent_of_prediction	percent_of_DWPC	metapath
Icosapent ethyl—Fungal infection—Mitoxantrone—lymphatic system cancer	0.00914	0.00914	CcSEcCtD
Icosapent ethyl—Myocardial ischaemia—Mitoxantrone—lymphatic system cancer	0.00878	0.00878	CcSEcCtD
Icosapent ethyl—Alopecia—Mechlorethamine—lymphatic system cancer	0.00812	0.00812	CcSEcCtD
Icosapent ethyl—Viral infection—Mitoxantrone—lymphatic system cancer	0.00781	0.00781	CcSEcCtD
Icosapent ethyl—Neck pain—Carmustine—lymphatic system cancer	0.00768	0.00768	CcSEcCtD
Icosapent ethyl—Dysphagia—Fludarabine—lymphatic system cancer	0.00744	0.00744	CcSEcCtD
Icosapent ethyl—Angina pectoris—Fludarabine—lymphatic system cancer	0.00725	0.00725	CcSEcCtD
Icosapent ethyl—Sweating—Teniposide—lymphatic system cancer	0.00724	0.00724	CcSEcCtD
Icosapent ethyl—Vertigo—Mechlorethamine—lymphatic system cancer	0.00719	0.00719	CcSEcCtD
Icosapent ethyl—Bronchitis—Fludarabine—lymphatic system cancer	0.00716	0.00716	CcSEcCtD
Icosapent ethyl—Sudden death—Methotrexate—lymphatic system cancer	0.00687	0.00687	CcSEcCtD
Icosapent ethyl—Neoplasm—Carmustine—lymphatic system cancer	0.00686	0.00686	CcSEcCtD
Icosapent ethyl—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00671	0.00671	CcSEcCtD
Icosapent ethyl—Pneumonia—Fludarabine—lymphatic system cancer	0.00667	0.00667	CcSEcCtD
Icosapent ethyl—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00654	0.00654	CcSEcCtD
Icosapent ethyl—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00653	0.00653	CcSEcCtD
Icosapent ethyl—Myocardial infarction—Fludarabine—lymphatic system cancer	0.0065	0.0065	CcSEcCtD
Icosapent ethyl—Arthritis—Bleomycin—lymphatic system cancer	0.0065	0.0065	CcSEcCtD
Icosapent ethyl—Infection—Mechlorethamine—lymphatic system cancer	0.00649	0.00649	CcSEcCtD
Icosapent ethyl—Epistaxis—Fludarabine—lymphatic system cancer	0.00626	0.00626	CcSEcCtD
Icosapent ethyl—Anorexia—Mechlorethamine—lymphatic system cancer	0.00623	0.00623	CcSEcCtD
Icosapent ethyl—Sinusitis—Fludarabine—lymphatic system cancer	0.00622	0.00622	CcSEcCtD
Icosapent ethyl—Chills—Teniposide—lymphatic system cancer	0.00608	0.00608	CcSEcCtD
Icosapent ethyl—Arrhythmia—Teniposide—lymphatic system cancer	0.00605	0.00605	CcSEcCtD
Icosapent ethyl—Alopecia—Teniposide—lymphatic system cancer	0.00599	0.00599	CcSEcCtD
Icosapent ethyl—Pharyngitis—Fludarabine—lymphatic system cancer	0.00591	0.00591	CcSEcCtD
Icosapent ethyl—Polyp—Methotrexate—lymphatic system cancer	0.00578	0.00578	CcSEcCtD
Icosapent ethyl—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Icosapent ethyl—Chills—Fludarabine—lymphatic system cancer	0.00534	0.00534	CcSEcCtD
Icosapent ethyl—Arrhythmia—Fludarabine—lymphatic system cancer	0.00532	0.00532	CcSEcCtD
Icosapent ethyl—Alopecia—Fludarabine—lymphatic system cancer	0.00526	0.00526	CcSEcCtD
Icosapent ethyl—Cyst—Methotrexate—lymphatic system cancer	0.00526	0.00526	CcSEcCtD
Icosapent ethyl—Malnutrition—Fludarabine—lymphatic system cancer	0.00519	0.00519	CcSEcCtD
Icosapent ethyl—Hypertension—Teniposide—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Icosapent ethyl—Chest pain—Teniposide—lymphatic system cancer	0.00502	0.00502	CcSEcCtD
Icosapent ethyl—Cardiac arrest—Vincristine—lymphatic system cancer	0.005	0.005	CcSEcCtD
Icosapent ethyl—Pneumonia—Bleomycin—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Icosapent ethyl—Oedema—Teniposide—lymphatic system cancer	0.00481	0.00481	CcSEcCtD
Icosapent ethyl—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00481	0.00481	CcSEcCtD
Icosapent ethyl—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Icosapent ethyl—Infection—Teniposide—lymphatic system cancer	0.00478	0.00478	CcSEcCtD
Icosapent ethyl—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Icosapent ethyl—Dysphagia—Carmustine—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Icosapent ethyl—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00474	0.00474	CcSEcCtD
Icosapent ethyl—Tachycardia—Teniposide—lymphatic system cancer	0.0047	0.0047	CcSEcCtD
Icosapent ethyl—Malaise—Fludarabine—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Icosapent ethyl—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Icosapent ethyl—Pruritus—Mechlorethamine—lymphatic system cancer	0.00462	0.00462	CcSEcCtD
Icosapent ethyl—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Icosapent ethyl—Anorexia—Teniposide—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Icosapent ethyl—Fungal infection—Methotrexate—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Icosapent ethyl—Cough—Fludarabine—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Icosapent ethyl—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Icosapent ethyl—Arthralgia—Fludarabine—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Icosapent ethyl—Myalgia—Fludarabine—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Icosapent ethyl—Discomfort—Fludarabine—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Icosapent ethyl—Hyperglycaemia—Carmustine—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Icosapent ethyl—Dyspnoea—Teniposide—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Icosapent ethyl—Pneumonia—Carmustine—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Icosapent ethyl—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Icosapent ethyl—Oedema—Fludarabine—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Icosapent ethyl—Infection—Fludarabine—lymphatic system cancer	0.0042	0.0042	CcSEcCtD
Icosapent ethyl—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Icosapent ethyl—Decreased appetite—Teniposide—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Icosapent ethyl—Vomiting—Mechlorethamine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Icosapent ethyl—Rash—Mechlorethamine—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Icosapent ethyl—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Icosapent ethyl—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Icosapent ethyl—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Icosapent ethyl—Pneumonia—Vincristine—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Icosapent ethyl—Anorexia—Fludarabine—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Icosapent ethyl—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Icosapent ethyl—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Icosapent ethyl—Myocardial infarction—Vincristine—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Icosapent ethyl—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Icosapent ethyl—Feeling abnormal—Teniposide—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Icosapent ethyl—Chills—Bleomycin—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Icosapent ethyl—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Icosapent ethyl—Sweating—Vincristine—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Icosapent ethyl—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Icosapent ethyl—Alopecia—Bleomycin—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Icosapent ethyl—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Icosapent ethyl—Body temperature increased—Teniposide—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Icosapent ethyl—Sweating—Mitoxantrone—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Icosapent ethyl—Dyspnoea—Fludarabine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Icosapent ethyl—Dyspepsia—Fludarabine—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Icosapent ethyl—Sinusitis—Mitoxantrone—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Icosapent ethyl—Decreased appetite—Fludarabine—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Icosapent ethyl—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Icosapent ethyl—Constipation—Fludarabine—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Icosapent ethyl—Pain—Fludarabine—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Icosapent ethyl—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Icosapent ethyl—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Icosapent ethyl—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Icosapent ethyl—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Icosapent ethyl—Asthenia—Teniposide—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Icosapent ethyl—Melaena—Methotrexate—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Icosapent ethyl—Malaise—Bleomycin—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Icosapent ethyl—Pruritus—Teniposide—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Icosapent ethyl—Arrhythmia—Carmustine—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Icosapent ethyl—Alopecia—Carmustine—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Icosapent ethyl—Body temperature increased—Fludarabine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Icosapent ethyl—Malnutrition—Carmustine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Icosapent ethyl—Cough—Bleomycin—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Icosapent ethyl—Myalgia—Bleomycin—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Icosapent ethyl—Chest pain—Bleomycin—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Icosapent ethyl—Alopecia—Vincristine—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Icosapent ethyl—Back pain—Carmustine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Icosapent ethyl—Discomfort—Bleomycin—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Icosapent ethyl—Chills—Mitoxantrone—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Icosapent ethyl—Neoplasm—Methotrexate—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Icosapent ethyl—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Icosapent ethyl—Alopecia—Mitoxantrone—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Icosapent ethyl—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Icosapent ethyl—Oedema—Bleomycin—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Icosapent ethyl—Infection—Bleomycin—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Icosapent ethyl—Back pain—Vincristine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Icosapent ethyl—Vomiting—Teniposide—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Icosapent ethyl—Asthenia—Fludarabine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Icosapent ethyl—Rash—Teniposide—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Icosapent ethyl—Dermatitis—Teniposide—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Icosapent ethyl—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Icosapent ethyl—Pruritus—Fludarabine—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Icosapent ethyl—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Icosapent ethyl—Back pain—Mitoxantrone—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Icosapent ethyl—Anorexia—Bleomycin—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Icosapent ethyl—Hypertension—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Icosapent ethyl—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Icosapent ethyl—Vertigo—Vincristine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Icosapent ethyl—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Icosapent ethyl—Chest pain—Carmustine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Icosapent ethyl—Myalgia—Carmustine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Icosapent ethyl—Malaise—Mitoxantrone—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Icosapent ethyl—Dyspnoea—Bleomycin—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Icosapent ethyl—Hypertension—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Icosapent ethyl—Oedema—Carmustine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Icosapent ethyl—Decreased appetite—Bleomycin—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Icosapent ethyl—Myalgia—Vincristine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Icosapent ethyl—Cough—Mitoxantrone—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Icosapent ethyl—Infection—Carmustine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Icosapent ethyl—Vomiting—Fludarabine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Icosapent ethyl—Rash—Fludarabine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Icosapent ethyl—Dermatitis—Fludarabine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Icosapent ethyl—Hypertension—Mitoxantrone—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Icosapent ethyl—Pain—Bleomycin—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Icosapent ethyl—Tachycardia—Carmustine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Icosapent ethyl—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Icosapent ethyl—Myalgia—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Icosapent ethyl—Chest pain—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Icosapent ethyl—Discomfort—Mitoxantrone—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Icosapent ethyl—Oedema—Vincristine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Icosapent ethyl—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Icosapent ethyl—Anorexia—Carmustine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Icosapent ethyl—Infection—Vincristine—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Icosapent ethyl—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Icosapent ethyl—Oedema—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Icosapent ethyl—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Icosapent ethyl—Infection—Mitoxantrone—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Icosapent ethyl—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Icosapent ethyl—Shock—Mitoxantrone—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Icosapent ethyl—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Icosapent ethyl—Anorexia—Vincristine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Icosapent ethyl—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Icosapent ethyl—Body temperature increased—Bleomycin—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Icosapent ethyl—Insomnia—Carmustine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Icosapent ethyl—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Icosapent ethyl—Mood swings—Methotrexate—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Icosapent ethyl—Dyspnoea—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Icosapent ethyl—Anorexia—Mitoxantrone—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Icosapent ethyl—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Icosapent ethyl—Decreased appetite—Carmustine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Icosapent ethyl—Insomnia—Vincristine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Icosapent ethyl—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Icosapent ethyl—Constipation—Carmustine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Icosapent ethyl—Pain—Carmustine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Icosapent ethyl—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Icosapent ethyl—Decreased appetite—Vincristine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Icosapent ethyl—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Icosapent ethyl—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Icosapent ethyl—Feeling abnormal—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Icosapent ethyl—Asthenia—Bleomycin—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Icosapent ethyl—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Icosapent ethyl—Constipation—Vincristine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Icosapent ethyl—Pain—Vincristine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Icosapent ethyl—Asthma—Methotrexate—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Icosapent ethyl—Pruritus—Bleomycin—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Icosapent ethyl—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Icosapent ethyl—Pancreatitis—Methotrexate—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Icosapent ethyl—Constipation—Mitoxantrone—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Icosapent ethyl—Pain—Mitoxantrone—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Icosapent ethyl—Body temperature increased—Carmustine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Icosapent ethyl—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Icosapent ethyl—Body temperature increased—Vincristine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Icosapent ethyl—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Icosapent ethyl—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Icosapent ethyl—Pneumonia—Methotrexate—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Icosapent ethyl—Vomiting—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Icosapent ethyl—Infestation NOS—Methotrexate—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Icosapent ethyl—Infestation—Methotrexate—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Icosapent ethyl—Rash—Bleomycin—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Icosapent ethyl—Dermatitis—Bleomycin—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Icosapent ethyl—Asthenia—Carmustine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Icosapent ethyl—Sweating—Methotrexate—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Icosapent ethyl—Epistaxis—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Icosapent ethyl—Asthenia—Vincristine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Icosapent ethyl—Asthenia—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Icosapent ethyl—Dizziness—Carmustine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Icosapent ethyl—Pharyngitis—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Icosapent ethyl—Vomiting—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Icosapent ethyl—Dizziness—Vincristine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Icosapent ethyl—Rash—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Icosapent ethyl—Dermatitis—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Icosapent ethyl—Vomiting—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Icosapent ethyl—Rash—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Icosapent ethyl—Dermatitis—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Icosapent ethyl—Vomiting—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Icosapent ethyl—Rash—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Icosapent ethyl—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Icosapent ethyl—Chills—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Icosapent ethyl—Alopecia—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Icosapent ethyl—Malnutrition—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Icosapent ethyl—Dysgeusia—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Icosapent ethyl—Back pain—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Icosapent ethyl—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Icosapent ethyl—Malaise—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Icosapent ethyl—Vertigo—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Icosapent ethyl—Cough—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Icosapent ethyl—Arthralgia—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Icosapent ethyl—Chest pain—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Icosapent ethyl—Myalgia—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Icosapent ethyl—Discomfort—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Icosapent ethyl—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Icosapent ethyl—Infection—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Icosapent ethyl—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Icosapent ethyl—Anorexia—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Icosapent ethyl—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Icosapent ethyl—Insomnia—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Icosapent ethyl—Dyspnoea—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Icosapent ethyl—Dyspepsia—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Icosapent ethyl—Decreased appetite—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Icosapent ethyl—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Icosapent ethyl—Pain—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Icosapent ethyl—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Icosapent ethyl—Body temperature increased—Methotrexate—lymphatic system cancer	0.000992	0.000992	CcSEcCtD
Icosapent ethyl—Asthenia—Methotrexate—lymphatic system cancer	0.0009	0.0009	CcSEcCtD
Icosapent ethyl—Pruritus—Methotrexate—lymphatic system cancer	0.000888	0.000888	CcSEcCtD
Icosapent ethyl—Dizziness—Methotrexate—lymphatic system cancer	0.00083	0.00083	CcSEcCtD
Icosapent ethyl—Vomiting—Methotrexate—lymphatic system cancer	0.000798	0.000798	CcSEcCtD
Icosapent ethyl—Rash—Methotrexate—lymphatic system cancer	0.000791	0.000791	CcSEcCtD
Icosapent ethyl—Dermatitis—Methotrexate—lymphatic system cancer	0.00079	0.00079	CcSEcCtD
